• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·RAY-B.ST
Share

RaySearch Laboratories AB Stocks

SEK 222.6Last Updated 12.06.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

SEK 792.61M

SEK 222.6
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

31.07.2025 18:00

Why European small caps are back on investors’ radar in 2025

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vast range of clinical activities. These capabilities include automated planning, adaptive therapy, multi-criteria optimization, rapid and accurate dose calculations, OAR dose reduction, robustness modeling, machine learning integration, and support for advanced radiation modalities such as VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic treatments, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also offers RayPlan, another treatment planning system specifically designed for various radiation therapy methods including 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy. For managing oncology workflows, RayCare serves as a dedicated information system. Additionally, RaySearch provides RayCommand, a flexible treatment control system compatible with diverse hardware and designed to manage advanced functionalities of treatment machines and software. To leverage patient data, its cloud-based oncology analytics system, RayIntelligence, converts raw information into valuable insights. RaySearch Laboratories AB (publ) further provides training courses for its products and is headquartered in Stockholm, Sweden.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of RAY-B.ST is 322 and suggests 51% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026